Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Maher

Showing results (871-880 of 1,158) with videos related to

Pageof 116
Sort By:
Frontiers in Medicine|February 6, 2025
Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot studySumaiah J Alarfaj, Sahar M El-Haggar, Sahar K Hegazy, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|January 15, 2013
Elevated nocturnal desaturation index predicts mortality in interstitial lung diseaseT J Corte, S J Wort, S Talbot, et al.
Respiratory Research|February 2, 2017
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosisPhilip L Molyneaux, Michael J Cox, Athol U Wells, et al.
Diagnostics (Basel, Switzerland)|July 29, 2025
Performance of Computed Tomography of the Kidneys, Ureter and Bladder in Non-Calculus Diagnoses: A Comparative Review of Non-Enhanced with Intravenous Contrast-Enhanced ImagingAlexander T O'Mahony, Michael G Waldron, David J Ryan, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
The European Respiratory Journal|March 9, 2019
Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohortIain Stewart, Tricia McKeever, Rebecca Braybrooke, et al.
The European Respiratory Journal|November 30, 2018
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort studyClaire M Nolan, Matthew Maddocks, Toby M Maher, et al.
Respirology (Carlton, Vic.)|November 30, 2013
Rituximab in severe, treatment-refractory interstitial lung diseaseGregory J Keir, Toby M Maher, Damien Ming, et al.
Clinical Radiology|January 20, 2021
Ultra-low-dose thoracic CT with model-based iterative reconstruction (MBIR) in cystic fibrosis patients undergoing treatment with cystic fibrosis transmembrane conductance regulators (CFTR)F Moloney, R G Kavanagh, N J Ronan, et al.
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
Pageof 116

Showing results (871-880 of 1,158) with videos related to

Sort By:
Pageof 116
Frontiers in Medicine|February 6, 2025
Effect of a high dose atorvastatin as adjuvant therapy to mesalamine in attenuating inflammation and symptoms in patients with ulcerative colitis: a randomized controlled pilot studySumaiah J Alarfaj, Sahar M El-Haggar, Sahar K Hegazy, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|January 15, 2013
Elevated nocturnal desaturation index predicts mortality in interstitial lung diseaseT J Corte, S J Wort, S Talbot, et al.
Respiratory Research|February 2, 2017
Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosisPhilip L Molyneaux, Michael J Cox, Athol U Wells, et al.
Diagnostics (Basel, Switzerland)|July 29, 2025
Performance of Computed Tomography of the Kidneys, Ureter and Bladder in Non-Calculus Diagnoses: A Comparative Review of Non-Enhanced with Intravenous Contrast-Enhanced ImagingAlexander T O'Mahony, Michael G Waldron, David J Ryan, et al.
The Lancet. Respiratory Medicine|October 4, 2019
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialToby M Maher, Tamera J Corte, Aryeh Fischer, et al.
The European Respiratory Journal|March 9, 2019
Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohortIain Stewart, Tricia McKeever, Rebecca Braybrooke, et al.
The European Respiratory Journal|November 30, 2018
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort studyClaire M Nolan, Matthew Maddocks, Toby M Maher, et al.
Respirology (Carlton, Vic.)|November 30, 2013
Rituximab in severe, treatment-refractory interstitial lung diseaseGregory J Keir, Toby M Maher, Damien Ming, et al.
Clinical Radiology|January 20, 2021
Ultra-low-dose thoracic CT with model-based iterative reconstruction (MBIR) in cystic fibrosis patients undergoing treatment with cystic fibrosis transmembrane conductance regulators (CFTR)F Moloney, R G Kavanagh, N J Ronan, et al.
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
Pageof 116